INTRODUCTION
Cigarette smoking remains a major health problem worldwide. The smoke from cigarettes consists of 4000-7000 complex chemical compounds, including the carcinogen nicotine [1, 2] . Multiple studies have shown that nicotine can enhance the progression of several cancers, including lung, colon, gastric and breast cancers [3] . There is considerable interest in the relationship between smoking and the onset and progression of breast cancer, which is the most common malignancy in women [4] and the second most common cause of death among women in the United States [5] . If diagnosed in the early stages, combinations of surgery, chemotherapy and radiotherapy can be viable treatments [6] , but drug resistance does occur. This study focused on the role of nicotine in the MCF-7 breast cancer cell line and its relationship to drug resistance. Nicotine interacts with nicotinic acetylcholine receptors (nAChRs), which activate signaling pathways that affect cancer progression and metastasis [7] . The nAChR structure is five subunits arranged as a hetero-or homopentamer to form a central ion channel. Neuronal and muscle nAChRs are composed of α7, α8, α9, α2-α6, β2-β4, β1, γ or δ subunits. Both the neuronal and muscle nAChR families are found in cancer cells [8] . Any study of proliferation, progress and metastasis in cancer must refer to the mechanisms of apoptosis. This process of cell death involves three steps: infusion, determination or decision, and performance. These can occur via an intrinsic or extrinsic pathway. The Bax subfamily, consisting of Bax, Bak and Bad, promotes apoptosis, and the Bcl-2 family regulates the determination phase of the process [9, 10] . The discovery that Bcl-2 protein is involved in the inhibition of apoptosis provided a new way of approaching cancer pathology, since tumor genesis can be due to unlimited proliferation or an inhibition or disruption of apoptosis. Bax is a major promoter of cell death in patients with cancer [11] . However, the mechanisms involved in regulating the pro-apoptotic activity of Bax are not fully known. Activation of the pro-apoptotic function of Bax likely occurs through various related mechanisms: cytosol transposition to the mitochondria [12] , oligomerization and entry into the mitochondrial membranes [13] . Bax is translocated into the mitochondria upon induction of apoptosis [14] . The translocation process involves a conformational change in Bax to expose its C-terminal hydrophobic domain [15] . After translocation, Bax forms an insertion of large oligomers in mitochondrial membranes, leading to cytochrome c distribution and cytotoxic events [15, 16] . Increasing evidence indicates that tobacco use can decrease the efficacy of cancer treatment and increase the risk of recurrence [16] . Recent studies have shown that nicotine inhibits chemotherapeutic drug-induced apoptosis of cancer cells [17] . It must also be recognized that apoptosis is not always a major mode of cell death in solid tumors [18, 19] . The recently revealed roles of nAChRs in carcinogenesis, proliferation, angiogenesis, apoptosis inhibition and metastasis in breast, lung and colon cancers are of considerable interest [20, 21] . In studies of colon and gastric cancer, a role was found for α7 nicotinic receptor in mediating cancer progression and metastasis [22, 23] . In this study, we compared the rates of apoptosis and the expressions of α7 nicotinic receptor, Bax and Bcl-2 in MCF-7 breast cancer cells exposed to nicotine and doxorubicin with the expressions in cells not exposed to nicotine.
MATERIALS AND METHODS

Cell culture
Human mammary gland epithelial adenocarcinomas from the MCF-7 cell line ATCC HTB 22 were obtained from the American Type Culture Collection. The cells were grown in Dulbecco's modified Eagle medium (DMEM), 10% fetal bovine serum (FBS), and 1% penicillin-streptomycin (all from Thermo Fisher Scientific, Inc.). Cells were sub-cultured and maintained as exponentially growing monolayers in a humidified 5% CO 2 -air atmosphere at 37ºC.
Nicotine solution
A solution consisting of 9.2 mg of nicotine in 1000 µl PBS was prepared for the pre-exposure and co-exposure experiments. Periods of exposure varied from 24 h to 72 h depending on the experiment. The conditions were a humidified 5% CO 2 -air atmosphere and temperature of 37ºC [24, 25] .
MTT assay for cell viability
Exponentially growing cells were harvested and plated in 96-well flat-bottom plates at 5,000 cells per well containing 200 ml of complete culture medium. The cells were allowed to attach overnight. Then, the cells were pretreated with 100 µl of 9.2 mg/ml nicotine for 24, 48 or 72 h followed by exposure to 1, 2, 3 or 5 µg/ml doxorubicin (DOX1, DOX2, DOC3 or DOX5) with or without nicotine for 24 h at 37ºC. Cell growth, proliferation and viability were measured using the MTT assay. Mitochondrial dehydrogenase levels, which are correlated to cell viability, were determined via enzyme-mediated cleaving of the tetrazolium salt ring of MTT to yield purple formazan crystals. These crystals were dissolved in isopropanol, and the absorption at 490 nm was determined spectrophotometrically.
Appropriate control experiments were run to determine the spectrophotometric background and absorption due to reagent blanks [24, 25] .
Protein isolation and western blotting
Based on unpublished data from experiments in which heteromeric nAChRs α1-α6 and β2-β4 could not be detected, α7 nicotinic receptor was selected for assessment. Cells were washed with PBS, lysed in ice-cold lysis buffer consisting of 50 mM Tris (pH 7.5), 150 mM NaCl and 0.5% Nonidet P-40 with protease inhibitor mixture set I (Calbiochem), then centrifuged at 14,000 rpm for 10 min at 4ºC. The supernatant was collected as the cell lysate, as described previously. Protein (20 µl) from each sample was resolved by 12% SDS-PAGE, transferred, and analyzed via western blotting. Antibodies were obtained from Santa Cruz Biotechnology: α7nAChR antibody (1:1000); anti β-actin antibody (1:1000), Bax antibody (1:1000); anti Bcl-2 antibody (1:1000); alkaline phosphatase-coupled anti-mouse antibody; and anti-rabbit IgG antibody. The specific protein complexes were identified with the chromogenic substrates nitro blue tetrazolium, and 5-bromo-4-chloro-3-indolyl-phosphate (BCIP; KPL). In each experiment, proteins were also probed with anti-β-actin antibodies as a protein-loading control [26, 27] .
RNA isolation
Total cellular RNA was isolated from MCF-7 cells treated with nicotine and control cells that had not been treated with nicotine. The cells were immediately immersed in 1.5 ml RNX + (Sigma-Aldrich) using a Dremel Model 395 Type 5. Total RNA was isolated according to the manufacturer's instructions, with 1 µl of chloroform solution (Sigma-Aldrich) added to the aqueous phase immediately before the addition of isopropanol. The final RNA pellets were dissolved in 50 µl diethyl pyrocarbonate-treated water (DEPC water) and the RNA yield was determined using a UV-3600 UV-VIS-NIR Spectrophotometer (Shimadzu) [28] .
Complementary DNA synthesis
Complementary DNA (cDNA) was made from 5 µl total RNA using 500 ng oligo (dT). RNA was reverse transcribed with 200 U Moloney murine leukemia virus reverse transcriptase [28] for 10 min at 70ºC and 60 min at 42ºC.
Primer design
Primers for α7 nicotinic receptor and β-actin genes were designed using NCBI BLAST. These primers were designed to be intron spanning to preclude amplification of genomic DNA. The primer sequences for α7 nicotinic receptor were 5'-GTCCCTGCAAGGCGAGTT'-3 (forward) and 5'-GCAGCCAATGT TGGTGG-3' (reverse) and for β-Actin were 5'-TGGCACCACACCTTCT ACAATG-3' (forward) and 5'-TCATCTTCTCGCGGTTGGC-3' (reverse).
Real-time qPCR
After conventional PCR was optimized and appropriate bands were obtained, qPCR was applied for the quantitative analysis of α7 nicotinic receptor gene expression. Serial dilutions of cDNA (0.1, 1, 10, and 100) were prepared, the concentrations were measured using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Inc.) and the reaction with primers for each gene was performed. In the first part, the curve for different dilutions of cDNA with primers corresponding to α7 nicotinic receptor gene was tested. Real-time qPCR was performed on a Gene Amp 5700 Sequence Detection System. Each 10-µl volume reaction used contained 1 µl QuantiTect SYBR Green PCR Master Mix (Qiagen), 0.1 U AmpErase UNG enzyme (Thermo Fisher Scientific, Inc.), 0.7 µl cDNA template and 0.25 µl of both forward and reverse primers. The initial step of PCR was 2 min at 55ºC for AmpErase UNG activation, followed by 15 min at 95ºC. Cycles (n = 40) consisted of a 15-s denaturation step at 95ºC, followed by a 1-min annealing/extension step at 55ºC. The final step was 60ºC incubation for 1 min. All reactions were performed in triplicate and β-actin was used as a housekeeping gene and RNA preparation control [25] .
Statistical analyses
Data analysis was performed using Q-Gene software (Qiagen; version 2-0-2-4, model 5-llex HRM), to express and normalize mean data expression. The mean normalized expression (MNE) is directly proportional to the amount of RNA of the target gene (i.e., α7 nicotinic receptor gene) relative to the amount of RNA of the reference gene (β-actin). The standard deviations (SD) were calculated with Q-Gene software using the differential equation of Gauss [29] . Analysis of variance (ANOVA) was used to compare differences between values using SPSS software version 16. p < 0.05 was considered significant.
RESULTS
Using the MTT assay, MCF-7 cells were examined for the effects of 24 h exposure to 1, 2, 3 or 5 µg/ml doxorubicin (Fig. 1) . DOX1 (1 µg/ml doxorubicin) had no significant toxic effects but DOX2 (2 µg/ml doxorubicin) was found to have a mild toxic effect. High levels of cell death were seen with DOX3 and DOX5 (3 and 5 µg/ml doxorubicin; p < 0.05). The MTT assay was also used to evaluate the viability of MCF-7 cells treated with different concentrations of doxorubicin after different durations of exposure to 100 µl of 9.2 mg/ml nicotine. Cells were treated with nicotine for 24 and 48 h, allowed to grow in 96-well plates for 24 h, and then exposed to the four concentrations of doxorubicin (1, 2, 3 or 5 µg/ml) for 24 h. The main control was MCF-7 cells that were not treated with doxorubicin and either not exposed to nicotine or exposed to nicotine for 24 or 48 h. There were also controls with doxorubicin exposure but no nicotine treatment. Fig. 2 shows that the cytotoxic drugs used still reduce the cell survival rate in a dose-dependent manner. DOX1 (1 µg/ml doxorubicin) had no significant toxic effects but DOX2 (2 µg/ml doxorubicin) was found to have a mild toxic effect Fig. 1 . The effects of different concentrations of doxorubicin on MCF-7 cells as observed using the MTT assay after 24 h exposure. The results are shown as means ± standard error. *Significant differences compared to control group. **No significant differences compared to control group. DOX1: 1 µg/ml doxorubicin; DOX2: 2 µg/ml doxorubicin; DOX3: 3 µg/ml doxorubicin; DOX5: 5 µg/ml doxorubicin. Fig. 2 . The interaction of nicotine pretreatment and doxorubicin treatment in MCF-7 cells expressed as cell viability assessed using the MTT assay. Cells were pretreated with nicotine for 24 or 48 h (grey Nicotine24 and mid-grey Nictotine48 bars, respectively) or not exposed to nicotine (black control bars) and then treated with 1, 2, 3 or 5 µg/ml doxorubicin for 24 h. The results for 3 and 5 µg/ml, designated DOX3 and DOX5, are shown. The main control group (designated Control on the x-axis) consisted of completely untreated cells (black bar), cells treated with nicotine for 24 h (grey bar) and cells treated with nicotine for 48 h (midgrey bar) with no doxorubicin exposure. Results are shown as means ± standard error. *Significant differences between the cell viability for the control group for this experimental set and the cell viability for the main control group. **No significant differences between these cells and the control group for this experimental set.
(not shown). High levels of cell death were still seen with DOX3 and DOX5 (3 and 5 µg/ml doxorubicin; p < 0.05) regardless of nicotine exposure, but there was a non-significant reduction in the effect of doxorubicin when the cells were pre-exposed to nicotine. Fig. 3 shows the results with 72 h pre-exposure to nicotine. All of the doses of doxorubicin had cytotoxic effects, but there was a significant difference (p < 0.05) between the cell viability of cells pre-exposed to nicotine for 72 h and then treated with 3 or 5 µg/ml doxorubicin for 24 h. Nicotine proved to have a protective effect on the cancer cells, determined as significant resistance to the drug's effect. Fig. 3 . The interaction of 72 h nicotine pretreatment and 24 h doxorubicin treatment in MCF-7 cells expressed as cell viability assessed using the MTT assay. Cells were pretreated with nicotine for 72 h (grey Nicotine72 bars) or not exposed to nicotine (black control bars) and then treated with 1, 2, 3 or 5 µg/ml doxorubicin for 24 h. The results for 2, 3 and 5 µg/ml, designated DOX2, DOX3 and DOX5, are shown. The main control group (designated Control on the x-axis) consisted of completely untreated cells (black bar) and cells treated with nicotine for 72 h with no doxorubicin exposure. Results are shown as means ± standard error. *Significant differences between the treatment group and the main control group. **No significant differences between the treatment group and the main control group.
#
Significant difference between the cell viability for doxorubicin-treated cells and the control group for this experimental set. Fig. 4 shows micrographs taken with a Nikon TS100 inverted microscope of the various experimental groups: those exposed to nicotine but not treated with doxorubicin (A series), the control cells with no exposure to nicotine or doxorubicin (B series), and the cells exposed to DOX3 with or without nicotine pre-exposure (C series) and DOX5 with or without nicotine pre-exposure (D series). Fig. 4 . Light micrographs of cancer cells exposed to nicotine and/or doxorubicin. A -Cells treated with nicotine for 72 h. Magnifications: a1 -40x; a2 -100x; a3 -250x. B -Control cells with no exposure to nicotine or doxorubicin. Magnifications: b1 -40x; b2 -100x; b3 -250x. C -Cells treated with 3 µg/ml doxorubicin without (c1 and c3) and with (c2 and c4) nicotine pretreatment. Magnifications: c1 and c2 -100x; c3 and c4 -250x. D -Cells treated with 5 µg/ml doxorubicin without (d1 and d3) and with (d2 and d4) nicotine pretreatment. Magnifications: d1 and d2 -100x; d3 and d4 -250x.
Western blotting was applied to assess apoptosis in the control groups and the groups treated with nicotine for 72 h. The activity of α7 nicotinic receptor and the levels of Bax and Bcl-2 protein were analyzed. β-actin was used as control. As shown in Fig. 5 , α7 nicotinic receptor protein expression in MCF-7 cells treated with nicotine was significantly higher (93.32%) than the level in untreated MCF-7 cells (76.55%). RNA was extracted from the cells in the control groups and the cells treated with nicotine, cDNA was synthesized, and PCR was performed using primers for β-actin. Temperature gradient PCR showed that 55ºC was the best temperature for the α7 nicotinic receptor. The results show that α7 nicotinic receptor gene expression was 0.159 times higher in MCF-7 cells treated with nicotine compared with the control, but this was not a significant difference (p > 0.05; Fig. 9 ).
DISCUSSION
In this study, we reported on the effect of nicotine on the expressions of the α7 nicotinic receptor gene and Bax and Bcl-2 proteins and their relationship to drug resistance in the breast cancer cell line MCF-7. These results are significant given the prevalence of health issues related to cigarette smoking. Cigarette smoke contains nicotine, which is considered a genotoxic carcinogen and a major important risk factor in the development of cancer. Cigarette smokers have a 20 times higher risk of developing cancer than nonsmokers. It is known that nicotinic acetylcholine receptors (nAChRs) are widely expressed in neurons, neuromuscular junctions, and cells such as epithelial cells from different organs and endothelial cells [30, 31] . They are also known to have a relationship to cell death or apoptosis and the control of cellular homeostasis. Bcl-2 and Bax proteins are also important in the cell death process. The relationship between a7 nicotinic receptor, Bax and Bcl-2 expression and nicotine is therefore one with serious implications for apoptosis. The transformation of normal cells into malignant tumors disrupts the balance between cell proliferation and apoptosis, leading to an increase in cell proliferation and a decrease in apoptosis. Cytotoxic drugs used in cancer treatment, such as doxorubicin, increase apoptosis in cancer cells [32, 33] . In our study, the measurement of cell survival using the MTT assay showed a reduction in doxorubicin-induced cell death in cells that had been pre-exposed to nicotine. In addition, we found that the levels of α7 nicotinic receptor and Bcl-2 protein increased, while the Bax protein level decreased. This concurs with results found by Lien et al. [22] , Mai et al. [34] and Assis et al. [35] . Several studies have shown that smoking correlates highly with the initiation, progression and metastasis of various cancers and that nicotine treatment can stimulate the expression of α9 nicotinic receptor and subsequently cause normal breast epithelia to transform to cancer cells. Suppression of nicotine-enhanced α9 nicotinic receptor expression through EGCG may reduce the progression of breast cancer cells [21, 22] . Nicotine in tobacco smoke induces the secretion of growth factors such as BFGF and VEGF, resulting in AKT or PKC and Raf pathway activation in lung epithelial or cancer cells. This also causes upregulation of Bcl-2 signaling, which is responsible for an increase in resistance to anti-cancer therapies [34] . Bcl-2 overexpression is observed in a wide variety of human cancers. It prevents the induction of apoptosis in neoplastic cells and contributes to resistance to chemotherapy [36] . Studies show nicotine exposure increases the resistance of cancer cells to the toxicity of anticancer drugs. Bcl-2 has an important role in nicotine-induced anti-apoptotic activities [37] . Results show that treatment of breast cancer cells with nicotine significantly protected against the cytotoxicity of doxorubicin [34, 35] . It has been found that Bcl-2 is one of the targets of nicotine. It appears that nicotine, through the activation of Src and AKT, promotes anti-apoptotic activity in breast cancer cells. AKT is involved in regulating the expression of Bcl-2 and is responsible for long-term survival of breast cancer cells [11, 35] . Nicotine accelerates cell proliferation by increasing levels of growth factors, such as VEGF and VEGFR-2 [37] . Nicotine can induce transactivation of the epidermal growth factor receptor (EGFR) through an increase in intracellular Ca 2+ and voltage-sensitive Ca 2+ channels. The mechanisms by which intracellular Ca 2+ causes transactivation of EGFR remain to be elucidated. The rise in Ca 2+ causes activation of cytoplasmic kinases, which then phosphorylate EGFR [38] . The inhibition of doxorubicin cytotoxicity by nicotine is in accordance with accumulating evidence that nicotine can affect the cytotoxicity of anticancer drugs [16, 17] . There is convincing evidence that nicotine upregulates anti apoptotic proteins such as XIAP, giving a survival advantage to certain lung cancer cells [17] . Nicotine has been shown to induce multisite phosphorylation of the pro-apoptotic proteins Bad and Bax in lung cancer cells and to suppress drug-induced apoptosis [16] , which could suggest that cancer cell resistance to doxorubicin treatment can increase upon nicotine exposure. Previously, researchers showed that programmed cell death (apoptosis) can occur in both tumor and normal tissue. It is known that apoptosis is the main mechanism for tumor cell death, although other modes of cell death in response to treatment are also important. Nicotine can affect the activity of signaling pathways that have a direct impact on the survival of cancer cells and the development of drug resistance [38] . Doxorubicin is a toxin linked to the cell cycle. It has proven quite effective in reducing the potential for cell survival [38] and has cytotoxic properties that affect several different mechanisms, including a plethora of free radicals. Free radicals formed through the action of doxorubicin can lead to DNA damage, which may in turn cause damage to cellular ATP levels or cell death by apoptosis [39] . However, nicotine can inhibit the cytotoxic effects of anticancer drugs such as doxorubicin through various mechanisms [40] , Here, we reported that the level of α7 nicotinic receptor gene expression was not significantly different to that in the control. Other studies showed an increase in α9 nicotinic receptor gene expression level after nicotine treatment. Interestingly, α7 nicotinic receptor protein expression increased without a significant increase in its gene expression. The most important finding of this research is that the Bcl-2 to Bax ratio protein in the cells increased with no significant changes in α7 nicotinic receptor gene expression [21, 41, 42] . This could be due to an effect on the expression of microRNAs (miRNAs), which are major non-coding RNA that are conserved evolutionarily and have a length of 18-25 nucleotides. MicroRNAs regulate protein expression at the posttranscriptional level either by translational inhibition or by degradation of target mRNAs. Physiological and pathological cellular processes controlled by companion RNA and proteins promote or inhibit tumor development [43] . Thus, mutations in the open reading frames can lead to cancer. Several factors can affect the expression patterns of miRNAs, including cancer, cigarette smoke, UV light and diesel particles. The targets of miRNAs include anti-apoptotic genes (Bcl-2 family), tumor suppressor genes (CDKN2, TP53) and oncogenes (Myc family, Ras family) [44] . For example, in lung cancer, one of the potential cigarette smoke-mediated deregulated miRNAs is mir-204. Bcl-2 and Mcl-1 are its gene targets. Previous studies showed that in lung cancer patients with a history of smoking, mir-204 is downregulated and mir-294 (as an oncomiR) is upregulated [45] . Such changes that occur after nicotine enters the cell may stimulate the anti-apoptotic protein (Bcl-2), resulting in a decrease in the rate of apoptosis and the induction of drug resistance. Since smoking cigarettes is still so prevalent, it is important to determine the function of nicotine in promoting tumorigenesis. In this study, we identified the direct effect of nicotine on apoptotic factors. Next, we plan to investigate the effect of specific antagonists for the studied receptors through in vivo studies.
CONCLUSIONS
Our data revealed that nicotine affects the resistance to doxorubicin-induced apoptosis in MCF-7 breast cancer cells. The increased resistance could be due to increases in the Bcl-2 to Bax ratio and in the expression of the α7 nicotinic receptor gene, which might be related to microRNA expression changes.
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